The reporting year saw buoyant demand for our CMM services, reflected in a high level of bookings, reaching into the medium term. Sales of recently launched products provided significant momentum. Chemical manufacturing was one of the key drivers behind the strong results returned by the Lonza Pharma&Biotech segment in 2017.
We strengthened the pipeline for development services, which led to further new product introductions at all chemical assets. Production of materials that require high-containment facilities continues to grow faster than the rest of our CMM business.
Another key highlight of the year was sustained investment in innovative business models, such as the start of construction of a mono-plant (dedicated API manufacturing plant) for Clovis in Visp (CH). Such projects are driven by customer demand and afford security of supply while allowing for flexibility to adapt to the changing needs of the product lifecycle.
In August 2017 we acquired Micro-Macinazione SA, based in Molinazzo (CH). As a market leader in the micronization of APIs and excipients, Micro-Macinazione extended our capacity for particle engineering in Europe. In combination with the Quakertown, PA (USA), micronization services from the Capsugel acquisition, Lonza now holds a leading position in contract micronization, which plays well to the market need to address bioavailability and solubility challenges. We are strongly positioned to provide a seamless service in micronized API production supporting customers globally from our European and U.S. facilities.